US5360496A
(en)
*
|
1991-08-26 |
1994-11-01 |
Aluminum Company Of America |
Nickel base alloy forged parts
|
CN1810832B
(zh)
|
1998-10-23 |
2012-12-12 |
麒麟-安姆根有限公司 |
与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
HUP0600342A3
(en)
*
|
2001-10-25 |
2011-03-28 |
Genentech Inc |
Glycoprotein compositions
|
DE60335915D1
(de)
*
|
2002-12-20 |
2011-03-10 |
Amgen Inc |
Myostatin hemmende bindungsstoffe
|
AU2005289685B2
(en)
|
2004-09-24 |
2009-07-16 |
Amgen Inc. |
Modified Fc molecules
|
SI1772465T1
(sl)
|
2005-01-05 |
2009-06-30 |
F Star Biotech Forsch & Entw |
Sintetične imunoglobulinske domene z modificiranimi vezavnimi lastnostmi v regijah molekule, ki se razlikujejo od komplementarnost dolučujočih regij
|
US7833979B2
(en)
|
2005-04-22 |
2010-11-16 |
Amgen Inc. |
Toxin peptide therapeutic agents
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
US7855279B2
(en)
*
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
US20090099031A1
(en)
*
|
2005-09-27 |
2009-04-16 |
Stemmer Willem P |
Genetic package and uses thereof
|
EP1929073A4
(fr)
*
|
2005-09-27 |
2010-03-10 |
Amunix Inc |
Produits pharmaceutiques proteiques et utilisations de ceux-ci
|
PL2500360T3
(pl)
*
|
2005-10-31 |
2016-01-29 |
Oncomed Pharm Inc |
Kompozycje i sposoby diagnozowania i leczenia nowotworu
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
CA2632544C
(fr)
*
|
2005-12-06 |
2014-09-23 |
Amgen Inc. |
Utilisations d'antagonistes de la myostatine
|
JO3324B1
(ar)
*
|
2006-04-21 |
2019-03-13 |
Amgen Inc |
مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
|
WO2007142954A2
(fr)
*
|
2006-05-30 |
2007-12-13 |
Dow Global Technologies Inc. |
Procédé d'optimisation d'un codon
|
US7981425B2
(en)
|
2006-06-19 |
2011-07-19 |
Amgen Inc. |
Thrombopoietic compounds
|
AT503889B1
(de)
*
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503902B1
(de)
*
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
US20090252703A1
(en)
*
|
2006-10-19 |
2009-10-08 |
Gegg Jr Colin V |
Use of alcohol co-solvents to improve pegylation reaction yields
|
WO2008088422A2
(fr)
*
|
2006-10-25 |
2008-07-24 |
Amgen Inc. |
Agents thérapeutiques à base de peptides toxiques
|
CA2669207A1
(fr)
*
|
2006-11-10 |
2008-05-15 |
Covx Technologies Ireland Limited |
Composes anti-angiogeniques
|
AU2011202645B2
(en)
*
|
2006-11-10 |
2012-07-12 |
Covx Technologies Ireland Limited |
Anti-angiogenic compounds
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
CA2687141C
(fr)
|
2007-05-22 |
2014-04-01 |
Amgen Inc. |
Compositions et procedes pour produire des proteines de fusion bioactives
|
PL3241842T3
(pl)
|
2007-06-26 |
2024-06-10 |
F-Star Therapeutics Limited |
Prezentacja środków wiążących
|
EP2078091A4
(fr)
*
|
2007-07-10 |
2010-09-01 |
Medimmune Llc |
Cristaux et structure du variant d'igg fc humain
|
US8933197B2
(en)
|
2007-08-15 |
2015-01-13 |
Amunix Operating Inc. |
Compositions comprising modified biologically active polypeptides
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
NZ586701A
(en)
*
|
2008-01-03 |
2013-07-26 |
Scripps Research Inst |
Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2)
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8580927B2
(en)
*
|
2008-01-31 |
2013-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
EP2113255A1
(fr)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Immunoglobuline cytotoxique
|
WO2009142460A2
(fr)
*
|
2008-05-23 |
2009-11-26 |
Samsung Electronics Co., Ltd. |
Corps synergique fusionné anticorps-peptide
|
US8637022B2
(en)
|
2008-06-30 |
2014-01-28 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Functionalized polypeptides
|
US7926951B2
(en)
*
|
2008-07-11 |
2011-04-19 |
Eastman Kodak Company |
Laser illuminated micro-mirror projector
|
JP5792621B2
(ja)
|
2008-09-26 |
2015-10-14 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
frizzled結合剤およびその使用
|
NZ627111A
(en)
|
2008-11-26 |
2015-10-30 |
Amgen Inc |
Variants of activin iib receptor polypeptides and uses thereof
|
US8680050B2
(en)
*
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
WO2010091122A1
(fr)
|
2009-02-03 |
2010-08-12 |
Amunix, Inc. |
Polypeptides recombinants étendus et compositions les comprenant
|
WO2010096394A2
(fr)
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
|
KR20110122846A
(ko)
*
|
2009-02-24 |
2011-11-11 |
알렉시온 파마슈티칼스, 인코포레이티드 |
치료용 tpo/epo 모방 펩티드를 포함하는 항체
|
WO2010108153A2
(fr)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Immunoglobulines porteuses et utilisations de celles-ci
|
US9849188B2
(en)
|
2009-06-08 |
2017-12-26 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
AU2010258898B8
(en)
|
2009-06-08 |
2015-02-05 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
EA020621B1
(ru)
|
2009-06-22 |
2014-12-30 |
Амген Инк. |
Рефолдинг белков с использованием химически контролируемого окислительно-восстановительного состояния
|
EP3660032A1
(fr)
|
2009-06-25 |
2020-06-03 |
Amgen, Inc |
Processus de purification de capture pour protéines exprimées dans un système non mammifère
|
US20120094874A1
(en)
*
|
2009-07-09 |
2012-04-19 |
F-Star Biotechnologische Forschungs-Und Entwicklungsges. M.B.H |
Stabilized immunoglobulin constant domains
|
US20120263701A1
(en)
*
|
2009-08-24 |
2012-10-18 |
Volker Schellenberger |
Coagulation factor vii compositions and methods of making and using same
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
AR080292A1
(es)
*
|
2010-02-24 |
2012-03-28 |
Emisphere Tech Inc |
Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml
|
MX347515B
(es)
|
2010-04-01 |
2017-04-28 |
Oncomed Pharmaceuticals Inc * |
Agentes que se unen al receptor encrespado y usos de los mismos.
|
WO2011123830A2
(fr)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Compositions d'alpha 1-antitrypsine, leurs procédés de préparation et d'utilisation
|
AU2011239470B2
(en)
|
2010-04-15 |
2015-09-10 |
Progenics Pharmaceuticals, Inc. |
Antibodies for the treatment of Clostridium difficile-associated infection and disease
|
EP2579897A1
(fr)
|
2010-06-08 |
2013-04-17 |
Genentech, Inc. |
Anticorps et conjugués modifiés par la cystéine
|
EP2407487A1
(fr)
|
2010-07-14 |
2012-01-18 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Anticorps modulaires multi-spécifiques
|
WO2012009705A1
(fr)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Complexes liant ang-2 et leurs utilisations
|
EP2598530A2
(fr)
|
2010-07-29 |
2013-06-05 |
Xencor, Inc. |
Anticorps dont les points isoélectriques sont modifiés
|
CN103339145A
(zh)
|
2010-09-22 |
2013-10-02 |
安姆根有限公司 |
运载体免疫球蛋白及其用途
|
US9884909B2
(en)
|
2010-12-01 |
2018-02-06 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
US9539324B2
(en)
|
2010-12-01 |
2017-01-10 |
Alderbio Holdings, Llc |
Methods of preventing inflammation and treating pain using anti-NGF compositions
|
US11214610B2
(en)
|
2010-12-01 |
2022-01-04 |
H. Lundbeck A/S |
High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
|
US9783602B2
(en)
|
2010-12-01 |
2017-10-10 |
Alderbio Holdings Llc |
Anti-NGF compositions and use thereof
|
US9078878B2
(en)
|
2010-12-01 |
2015-07-14 |
Alderbio Holdings Llc |
Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
|
US9067988B2
(en)
|
2010-12-01 |
2015-06-30 |
Alderbio Holdings Llc |
Methods of preventing or treating pain using anti-NGF antibodies
|
CA2824143C
(fr)
|
2011-01-14 |
2018-12-18 |
Redwood Bioscience, Inc. |
Immunoglobulines polypeptidiques a marquage aldehydique et leur methode d'utilisation
|
US9340590B2
(en)
|
2011-03-16 |
2016-05-17 |
Amgen Inc. |
Potent and selective inhibitors of NaV1.3 and NaV1.7
|
PT2691417T
(pt)
|
2011-03-29 |
2018-10-31 |
Roche Glycart Ag |
Variantes de fc de anticorpos
|
CN103702682A
(zh)
|
2011-04-21 |
2014-04-02 |
科罗拉多州立大学董事会法人团体 |
治疗视神经脊髓炎的组合物和方法
|
ES2704038T3
(es)
|
2011-05-24 |
2019-03-13 |
Zyngenia Inc |
Complejos multiespecíficos multivalentes y monovalentes y sus usos
|
EP2546268A1
(fr)
|
2011-07-13 |
2013-01-16 |
F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. |
Immunoglobuline s'internalisant
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
MX358358B
(es)
|
2011-12-19 |
2018-08-15 |
Amgen Inc |
Polipeptidos de receptores de activina variantes y sus usos.
|
KR102208698B1
(ko)
|
2011-12-21 |
2021-01-29 |
암젠 인크 |
신생아 Fc 수용체에 대해 향상된 결합을 지니는 변이체 Fc-폴리펩타이드
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP2822577B1
(fr)
|
2012-02-15 |
2019-02-06 |
Bioverativ Therapeutics Inc. |
Protéines de facteur viii de recombinaison
|
LT2814840T
(lt)
|
2012-02-15 |
2020-02-25 |
Bioverativ Therapeutics Inc. |
Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
|
WO2013130683A2
(fr)
|
2012-02-27 |
2013-09-06 |
Amunix Operating Inc. |
Compositions de conjugués xten et leurs procédés de préparation
|
WO2013184514A1
(fr)
*
|
2012-06-04 |
2013-12-12 |
Irm Llc |
Méthodes de marquage spécifiques à un site et molécules ainsi produites
|
US11142563B2
(en)
*
|
2012-06-14 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing modified Fc region
|
ES2896493T3
(es)
|
2012-07-13 |
2022-02-24 |
Roche Glycart Ag |
Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
|
WO2014022102A1
(fr)
|
2012-08-01 |
2014-02-06 |
Amgen Inc. |
Procédés d'utilisation de composés anti-apoptotiques pour moduler une ou plusieurs propriétés d'une culture de cellules
|
WO2014030750A1
(fr)
|
2012-08-24 |
2014-02-27 |
中外製薬株式会社 |
ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS
|
US9834597B2
(en)
|
2012-09-21 |
2017-12-05 |
The Regents Of The University Of California |
Modified FC polypeptides, FC conjugates, and methods of use thereof
|
CN104768579A
(zh)
|
2012-10-23 |
2015-07-08 |
昂科梅德制药有限公司 |
使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
|
US10766960B2
(en)
|
2012-12-27 |
2020-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Heterodimerized polypeptide
|
EP2943512A4
(fr)
|
2013-01-11 |
2016-06-01 |
California Inst Biomedical Res |
Anticorps bovins de fusion
|
WO2014109858A1
(fr)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Méthodes d'utilisation d'inhibiteurs de cycle cellulaire pour moduler une ou plusieurs propriétés d'une culture cellulaire
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
CA2897987A1
(fr)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Elimination rapide de complexes antigeniques a l'aide de nouveaux anticorps
|
CN105431455A
(zh)
|
2013-02-01 |
2016-03-23 |
圣塔玛丽亚生物疗法公司 |
抗激活素a化合物对受试者的施用
|
JP2016510411A
(ja)
|
2013-02-04 |
2016-04-07 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路インヒビターによる処置の方法およびモニタリング
|
KR102447350B1
(ko)
|
2013-02-08 |
2022-09-23 |
노파르티스 아게 |
면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
|
WO2014165277A2
(fr)
|
2013-03-12 |
2014-10-09 |
Amgen Inc. |
Inhibiteurs sélectifs et puissants de nav1.7
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(ar)
*
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2968463A4
(fr)
*
|
2013-03-15 |
2016-11-23 |
Amgen Inc |
Antagonisme de la myostatine chez des sujets humains
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
AU2014232416B2
(en)
|
2013-03-15 |
2017-09-28 |
Xencor, Inc. |
Modulation of T Cells with Bispecific Antibodies and FC Fusions
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
SG10201800800YA
(en)
|
2013-05-06 |
2018-03-28 |
Scholar Rock Inc |
Compositions and methods for growth factor modulation
|
EP3033097B1
(fr)
|
2013-08-14 |
2021-03-10 |
Bioverativ Therapeutics Inc. |
Fusions de factor viii-xten et leurs utilisations.
|
WO2015035405A1
(fr)
*
|
2013-09-09 |
2015-03-12 |
Pinta Biotherapeutics, Inc. |
Antagoniste de la myostatine pour le traitement de la dénutrition protéino-énergétique chez des patients atteints d'insuffisance rénale terminale
|
AU2014342232B2
(en)
|
2013-10-31 |
2017-12-21 |
Amgen Inc. |
Use of monensin to regulate glycosylation of recombinant proteins
|
TWI652279B
(zh)
|
2013-11-11 |
2019-03-01 |
中外製藥股份有限公司 |
含改變的抗體可變區之抗原結合分子
|
US10106829B2
(en)
|
2014-01-29 |
2018-10-23 |
Amgen Inc. |
Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
|
KR102410393B1
(ko)
|
2014-01-29 |
2022-06-16 |
암젠 인크 |
재조합 단백질의 글리코실화를 조절하기 위한 n-글리코실화 경로 조절자의 과발현
|
EA201691925A1
(ru)
|
2014-03-28 |
2017-06-30 |
Ксенкор, Инк. |
Биспецифические антитела, которые связываются с cd38 и cd3
|
CA2943919A1
(fr)
|
2014-03-29 |
2015-10-08 |
Intas Pharmaceuticals Ltd. |
Composition pharmaceutique lyophilisee de proteine fusionnee avec un fc-peptide
|
WO2015187733A2
(fr)
*
|
2014-06-02 |
2015-12-10 |
Pinta Biotherapeutics, Inc. |
Inhibiteurs de la myostatine pour le traitement du diabète
|
WO2015188135A1
(fr)
*
|
2014-06-06 |
2015-12-10 |
The California Institute For Biomedical Research |
Protéines de fusion à anticorps à région constante et compositions les contenant
|
AR101844A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos y conjugados modificados genéticamente con cisteína
|
TW202313697A
(zh)
|
2014-11-11 |
2023-04-01 |
日商中外製藥股份有限公司 |
包含經改變之抗體可變區之抗原結合分子的資料庫
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
PE20171103A1
(es)
|
2014-11-26 |
2017-08-07 |
Xencor Inc |
Anticuerpos heterodimericos que se unen a cd3 y cd38
|
WO2016105450A2
(fr)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Anticorps trispécifiques
|
WO2016141387A1
(fr)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
|
US11215616B2
(en)
|
2015-04-10 |
2022-01-04 |
National Institutes Of Health (Nih), (Dhhs), U.S. Government |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
EP4129327A1
(fr)
|
2015-08-28 |
2023-02-08 |
Amunix Pharmaceuticals, Inc. |
Ensemble polypeptides chimériques et leurs procédés de préparation et d'utilisation
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
US10227410B2
(en)
|
2015-12-07 |
2019-03-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
KR102501335B1
(ko)
*
|
2015-12-18 |
2023-02-17 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
|
CN109153728A
(zh)
|
2016-03-21 |
2019-01-04 |
埃尔斯塔治疗公司 |
多特异性和多功能分子及其用途
|
KR20180135458A
(ko)
|
2016-04-26 |
2018-12-20 |
알.피.쉐러 테크놀러지즈 엘엘씨 |
항체 컨쥬게이트 및 이의 제조 및 이용 방법
|
CA3024027A1
(fr)
|
2016-05-11 |
2017-11-16 |
Amgen Inc. |
Selection directe de cellules exprimant des teneurs elevees en proteines heteromeres a l'aide de vecteurs de complementation intragenique de glutamine synthetase
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
JP7021127B2
(ja)
|
2016-06-28 |
2022-02-16 |
ゼンコア インコーポレイテッド |
ソマトスタチン受容体2に結合するヘテロ二量体抗体
|
CA3026050A1
(fr)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition pour la prophylaxie ou le traitement de maladies liees a il-8
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
WO2018222901A1
(fr)
|
2017-05-31 |
2018-12-06 |
Elstar Therapeutics, Inc. |
Molécules multispécifiques se liant à une protéine de leucémie myéloproliférative (mpl) et leurs utilisations
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
GB201711208D0
(en)
|
2017-07-12 |
2017-08-23 |
Iontas Ltd |
Ion channel inhibitors
|
SG11202000801QA
(en)
*
|
2017-07-31 |
2020-02-27 |
Univ Tokyo |
Highly versatile method of presenting cyclic peptide on protein structure
|
WO2019035938A1
(fr)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
Molécules multispécifiques se liant à bcma et leurs utilisations
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
US11952422B2
(en)
|
2017-12-05 |
2024-04-09 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
|
JP2021506291A
(ja)
|
2017-12-19 |
2021-02-22 |
ゼンコア インコーポレイテッド |
改変されたil−2 fc融合タンパク質
|
WO2019178362A1
(fr)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Molécules multifonctionnelles se liant à calréticuline et utilisations associees
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
CA3097741A1
(fr)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Proteines de fusion heterodimeres ciblant tim-3 contenant des proteines de fusion fc d'il-15/il-15ra et domaines de liaison a l'antigene de tim-3
|
MX2020012227A
(es)
*
|
2018-05-17 |
2021-04-13 |
Immunome Inc |
Epítopos marcadores del dominio ch3.
|
AU2019270184A1
(en)
|
2018-05-18 |
2020-11-26 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilia A
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
WO2020027224A1
(fr)
*
|
2018-07-31 |
2020-02-06 |
国立大学法人東京大学 |
Procédé super-polyvalent permettant de conférer une nouvelle spécificité de liaison à un anticorps
|
EP3861016A2
(fr)
|
2018-10-03 |
2021-08-11 |
Xencor, Inc. |
Protéines de fusion fc hétérodimères d'il -12
|
AU2019410643A1
(en)
|
2018-12-21 |
2021-08-12 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific protein
|
JP2022522662A
(ja)
|
2019-02-21 |
2022-04-20 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
AU2020226904A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
JP2022521937A
(ja)
|
2019-02-21 |
2022-04-13 |
マレンゴ・セラピューティクス,インコーポレーテッド |
NKp30に結合する抗体分子およびその使用
|
CA3130754A1
(fr)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Molecules multifonctionnelles se liant a des cellules cancereuses associees a des lymphocytes t et leurs utilisations
|
JP2022521750A
(ja)
|
2019-02-21 |
2022-04-12 |
マレンゴ・セラピューティクス,インコーポレーテッド |
カルレティキュリンに結合する多機能性分子およびその使用
|
CN114173875A
(zh)
|
2019-03-01 |
2022-03-11 |
Xencor股份有限公司 |
结合enpp3和cd3的异二聚抗体
|
CN113677702A
(zh)
|
2019-04-01 |
2021-11-19 |
诺和诺德股份有限公司 |
针对利拉鲁肽的抗体及其用途
|
WO2021041715A2
(fr)
*
|
2019-08-30 |
2021-03-04 |
University Of Kansas |
Compositions comprenant des mutations de fc d'igg et leurs utilisations
|
WO2021138407A2
(fr)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Molécules multifonctionnelles se liant à cd33 et utilisations associées
|
CA3170819A1
(fr)
|
2020-03-27 |
2021-09-30 |
Biotest Ag |
Proteine comprenant au moins un epitope d'activation des lymphocytes t regulateurs
|
AU2021250186A1
(en)
|
2020-03-31 |
2022-12-01 |
Chugai Seiyaku Kabushiki Kaisha |
DLL3-targeting multispecific antigen-binding molecules and uses thereof
|
WO2021217085A1
(fr)
|
2020-04-24 |
2021-10-28 |
Marengo Therapeutics, Inc. |
Molécules multifonctionnelles se liant à des cellules cancéreuses associées à des lymphocytes t et leurs utilisations
|
WO2021231976A1
(fr)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
|
CA3192204A1
(fr)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anticorps anti-cd28 et/ou compositions anti-b7h3
|
CA3190755A1
(fr)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Molecules multifonctionnelles se liant a la calreticuline et utilisations associees
|
WO2022046922A2
(fr)
|
2020-08-26 |
2022-03-03 |
Marengo Therapeutics, Inc. |
Molécules d'anticorps se liant à nkp30 et utilisations associees
|
JP2023540248A
(ja)
|
2020-08-26 |
2023-09-22 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Trbc1またはtrbc2を検出する方法
|
TW202233660A
(zh)
|
2020-10-30 |
2022-09-01 |
美商安進公司 |
過表現胰島素樣生長因子受體突變體以調節igf補充
|
CA3212665A1
(fr)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Anticorps heterodimeriques se liant a cd3 et a cldn6
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
JP2024515591A
(ja)
|
2021-04-08 |
2024-04-10 |
マレンゴ・セラピューティクス,インコーポレーテッド |
Tcrに結合する多機能性分子およびその使用
|
CN113402614A
(zh)
*
|
2021-04-22 |
2021-09-17 |
山东泉港药业有限公司 |
血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
|
WO2022245259A1
(fr)
*
|
2021-05-18 |
2022-11-24 |
Акционерное общество "ГЕНЕРИУМ" |
Procédé de purification industrielle de romiplostim
|
MX2023014680A
(es)
|
2021-06-10 |
2024-01-12 |
Amgen Inc |
Variantes genomodificadas de la nrg-1 con una selectividad mejorada frente al erbb4 pero no frente al erbb3.
|
WO2023044774A1
(fr)
*
|
2021-09-24 |
2023-03-30 |
Sichuan Clover Biopharmaceuticals, Inc. |
Protéines de fusion mimétiques de tpo et procédés d'utilisation de la soumission de listage de séquences dans un fichier de texte ascii
|
WO2023173084A1
(fr)
|
2022-03-11 |
2023-09-14 |
University Of Rochester |
Cyclopepticorps et leurs utilisations
|
WO2024133908A1
(fr)
|
2022-12-23 |
2024-06-27 |
Syna Therapeutics, S.L. |
Compositions pharmaceutiques stables comprenant du romiplostim
|